stoxline Quote Chart Rank Option Currency Glossary
TherapeuticsMD, Inc. (TXMD)
1.801  -0.069 (-3.69%)    07-17 16:00
Open: 1.85
High: 1.9
Volume: 9,836
Pre. Close: 1.87
Low: 1.771
Market Cap: 21(M)
Technical analysis
2024-07-17 5:30:53 PM
Short term     
Mid term     
Targets 6-month :  2.44 1-year :  2.85
Resists First :  2.08 Second :  2.44
Pivot price 1.72
Supports First :  1.68 Second :  1.43
MAs MA(5) :  1.82 MA(20) :  1.75
MA(100) :  2.06 MA(250) :  2.52
MACD MACD :  -0.1 Signal :  -0.1
%K %D K(14,3) :  84 D(3) :  82.4
RSI RSI(14): 47.9
52-week High :  4.34 Low :  1.43
Price, MAs and Bollinger Bands

Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.
[ TXMD ] has closed below upper band by 31.0%. Bollinger Bands are 12% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

Stock Price Prediction
If tomorrow: Open lower Open higher
High: 1.9 - 1.91 1.91 - 1.92
Low: 1.75 - 1.76 1.76 - 1.77
Close: 1.79 - 1.8 1.8 - 1.81
Company Description

TherapeuticsMD, Inc. operates as a women's healthcare company in the United States. The company offers IMVEXXY for the treatment of moderate-to-severe dyspareunia; BIJUVA, a bio-identical hormone therapy combination of 17ß-estradiol and progesterone for the treatment of moderate-to-severe vasomotor symptoms; and ANNOVERA, a ring-shaped contraceptive vaginal system. Its preclinical projects include the development of TX-005HR, a progesterone-alone transdermal cream; TX-006HR, an estradiol and progesterone transdermal cream; TX-007HR and TX-008HR, which are transdermal patch product candidates; and TX-009HR, an oral progesterone and estradiol formulation. It also manufactures and distributes branded and generic prescription prenatal vitamins under the vitaTrue, vitaPearl, vitaMedMD, and BocaGreenMD Prena1 brands. The company sells its prescription pharmaceutical products and prenatal vitamin products to wholesale distributors and retail pharmacy distributors. TherapeuticsMD, Inc. was founded in 2008 and is headquartered in Boca Raton, Florida.

Headline News

Fri, 12 Jul 2024
TherapeuticsMD, Inc. (NASDAQ:TXMD) Short Interest Up 57.7% in June - Defense World

Fri, 12 Jul 2024
TherapeuticsMD (NASDAQ:TXMD) Receives New Coverage from Analysts at - Defense World

Thu, 11 Jul 2024
TherapeuticsMD Inc. stock outperforms competitors on strong trading day - MarketWatch

Wed, 10 Jul 2024
TherapeuticsMD Inc. stock underperforms Wednesday when compared to competitors - MarketWatch

Mon, 24 Jun 2024 Initiates Coverage on TherapeuticsMD (NASDAQ:TXMD) - Defense World

Fri, 29 Mar 2024
TherapeuticsMD Announces Full Year 2023 Financial Results - Yahoo Finance

Financial Analysis
Price to Book Value:
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Price to Earnings:
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Discounted cash flow:
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Return on Assets:
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Return on Equity:
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Debt to Equity:
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Stock Basics & Statistics
Drug Manufacturers - Specialty & Generic
Shares Out 12 (M)
Shares Float 10 (M)
Held by Insiders 1.7 (%)
Held by Institutions 44.5 (%)
Shares Short 34 (K)
Shares Short P.Month 39 (K)
Stock Financials
EPS -0.57
EPS Est Next Qtrly 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 2.49
Profit Margin 0 %
Operating Margin -364.9 %
Return on Assets (ttm) -8.7 %
Return on Equity (ttm) -20.5 %
Qtrly Rev. Growth -24.8 %
Gross Profit (p.s.) 0
Sales Per Share 0.1
EBITDA (p.s.) -0.59
Qtrly Earnings Growth 0 %
Operating Cash Flow -15 (M)
Levered Free Cash Flow -16 (M)
Stock Valuations
PE Ratio -3.16
PEG Ratio 0
Price to Book value 0.72
Price to Sales 17.3
Price to Cash Flow -1.39
Stock Dividends
Dividend 0
Forward Dividend 0
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.

StockChart iOS

StoxlineLite iOS

StoxlineLite iOS

OptionCalc iOS

StockChart Android

StoxlineLite Android

StoxlinePro Android

OptionCalc Android